Related Experiment Video

Updated: May 23, 2026

Simultaneous Measurement of HDAC1 and HDAC6 Activity in HeLa Cells Using UHPLC-MS
09:20

Simultaneous Measurement of HDAC1 and HDAC6 Activity in HeLa Cells Using UHPLC-MS

Published on: August 10, 2017

Clinical development of histone deacetylase inhibitor romidepsin

P Guan1, H Fang

  • 1Department of Medicinal Chemistry, School of Pharmacy, Shandong University, Ji'nan, Shandong, China.

Drug Discoveries & Therapeutics
|April 12, 2012
PubMed

Insights

Histone deacetylase inhibitors, like romidepsin, show promise for cancer treatment. Romidepsin is approved for cutaneous T-cell lymphoma (CTCL) and demonstrates efficacy in various blood cancers.

Area of Science:

  • Oncology
  • Epigenetics
  • Pharmacology

Background:

  • Histone deacetylase inhibitors (HDACi) represent a significant advancement in epigenetic cancer therapy.
  • Romidepsin received US FDA approval in 2009 for treating cutaneous T-cell lymphoma (CTCL).

Purpose of the Study:

  • To detail the current clinical evaluation status of romidepsin.
  • To summarize its efficacy and safety profile across various hematological malignancies and solid tumors.

Main Methods:

  • Review of Phase I/II clinical trials data.
  • Analysis of romidepsin's performance as monotherapy and combination therapy.

Main Results:

  • Romidepsin demonstrated substantial efficacy in CTCL and peripheral T-cell lymphoma.
  • Marginal efficacy was observed in other hematological malignancies and solid tumors.
  • The drug exhibited a tolerable safety and toxicity profile.

Conclusions:

  • Romidepsin is an effective epigenetic therapy for specific lymphomas.
  • Its clinical utility extends beyond CTCL, warranting further investigation in other cancers.

More Related Videos

Assays for Validating Histone Acetyltransferase Inhibitors09:11

Assays for Validating Histone Acetyltransferase Inhibitors

Published on: August 6, 2020

Single-Step Enrichment of a TAP-Tagged Histone Deacetylase of the Filamentous Fungus Aspergillus nidulans for Enzymatic Activity Assay09:07

Single-Step Enrichment of a TAP-Tagged Histone Deacetylase of the Filamentous Fungus Aspergillus nidulans for Enzymatic Activity Assay

Published on: May 1, 2019

Related Concept Videos

Preclinical Development: Overview01:28

Preclinical Development: Overview

Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
Histone Modification02:32

Histone Modification

The histone proteins have a flexible N-terminal tail extending out from the nucleosome. These histone tails are often subjected to post-translational modifications such as acetylation, methylation, phosphorylation, and ubiquitination. Particular combinations of these modifications form “histone codes” that influence the chromatin folding and tissue-specific gene expression.
Acetylation
The enzyme histone acetyltransferase adds acetyl group to the histones. Another enzyme, histone deacetylase,...
Histone Modification02:32

Histone Modification

The histone proteins have a flexible N-terminal tail extending out from the nucleosome. These histone tails are often subjected to post-translational modifications such as acetylation, methylation, phosphorylation, and ubiquitination. Particular combinations of these modifications form “histone codes” that influence the chromatin folding and tissue-specific gene expression.
Acetylation
The enzyme histone acetyltransferase adds acetyl group to the histones. Another enzyme, histone deacetylase,...